☆ 4.6 Review

Optimizing the first-line treatment for metastatic colorectal cancer

FRONTIERS IN ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107.

Van K. Morris et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Jun Tian et al.

Summary: Combining PD-1, BRAF, and MEK inhibitors in BRAF(V600E) colorectal cancer patients resulted in a favorable overall response rate and durability. Translational analyses suggest that induction of tumor-intrinsic immune programs contributes to improved outcomes via MAPK inhibition.

NATURE MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Rona Yaeger et al.

Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Review Oncology

Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer

Javier Ros et al.

Summary: Immune checkpoint inhibitors have revolutionized the prognosis for several tumor types, but have shown limited success in treating metastatic colorectal tumors that are microsatellite stable (MSS). However, recent studies have demonstrated promising results with novel combinations of immune checkpoint inhibitors in MSS colorectal cancer. This review examines the underlying biological factors contributing to the lack of response to immunotherapy in MSS colorectal cancer and explores potential strategies to overcome innate resistance mechanisms.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

BREAKWATER: An open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E) + cetuximab (C) ± chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC).

Scott Kopetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.

David S. Hong et al.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic Colorectal Cancer

Eric Van Cutsem et al.

Summary: This study aimed to evaluate the efficacy, safety, and quality of life of the combination of encorafenib + binimetinib + cetuximab as first-line treatment for BRAF(V600E)-mutated mCRC. The results showed that this combination therapy was effective with a manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

John H Strickler et al.

LANCET ONCOLOGY (2023)

Add to Collection

Review Gastroenterology & Hepatology

Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond

Samar Al Bitar et al.

Summary: Colorectal cancer (CRC) is a common and deadly disease, with resistance to therapy becoming a major concern. Targeted therapies have shown promise in improving outcomes for patients with metastatic CRC (mCRC), including those who do not benefit from standard chemotherapy. Ongoing clinical trials are evaluating new targeted agents and exploring strategies to combat resistance. This review summarizes recent developments in targeted therapy for drug-resistant CRC and mCRC, addressing limitations and challenges, as well as the importance of personalized treatment selection based on predictive biomarkers.

WORLD JOURNAL OF GASTROENTEROLOGY (2023)

Add to Collection

Article Oncology

Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy A Phase 1 Nonrandomized Clinical Trial

Marwan Fakih et al.

Summary: The study aimed to determine the RP2D of regorafenib, ipilimumab, and nivolumab in patients with MSS metastatic colorectal cancer and evaluate its activity. The results suggest that RIN demonstrated interesting clinical activity in patients with advanced MSS colorectal cancer without liver metastases, and these findings need to be confirmed in randomized clinical trials.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology

Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: A phase 2 trial

Xianhua Fu et al.

Summary: The combination of pyrotinib and trastuzumab showed promising efficacy and manageable safety in patients with RAS/BRAF wild-type HER2-positive advanced colorectal cancer.

CANCER SCIENCE (2023)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of different maintenance strategies for RAS wild-type colorectal cancer: A network meta-analysis

Fausto Petrelli et al.

DIGESTIVE AND LIVER DISEASE (2023)

Add to Collection

Article Medicine, General & Internal

Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Marwan Fakih et al.

Summary: This study evaluated the efficacy and safety of regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair-proficient metastatic colorectal cancer. The results showed a certain level of activity in this patient population. However, further studies are needed to identify which patients would benefit most from treatment with regorafenib plus nivolumab.

ECLINICALMEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer

Valerie Boige et al.

Summary: This study evaluated the efficacy and safety of maintenance therapy with single-agent cetuximab after FOLFIRI induction therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). The study showed that cetuximab maintenance therapy significantly improved the 6-month progression-free rate.

JAMA NETWORK OPEN (2023)

Add to Collection

Meeting Abstract Oncology

Nivolumab (NIVO)+5-fluorouracil/leucovorin/oxaliplatin (mFOLFOX6)/bevacizumab (BEV) versus mFOLFOX6/BEV for first-line (1L) treatment of metastatic colorectal cancer (mCRC): Phase 2 results from CheckMate 9X8

Heinz-Josef Lenz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAF(V600E) metastatic colorectal cancer

Van K. Morris et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC)

Afsaneh Barzi et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

A phase II study of pembrolizumab, binimetinib, and bevacizumab in patients with microsatellitestable, refractory, metastatic colorectal cancer (mCRC)

Tyler Friedrich et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Immunology

The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma

Ting Ye et al.

Summary: This study identified MAP2K1/2 gene mutations as an independent predictive factor for anti-CTLA-4 therapy in melanoma patients. Anti-CTLA-4 treatment may be more effective than anti-PD-1 therapy for patients with MAP2K1/2-mutated melanoma.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Treatments after Immune Checkpoint Inhibitors in Patients with dMMR/MSI Metastatic Colorectal Cancer

Quang Loc Bui et al.

Summary: This study retrospectively collected clinical data from 31 patients with dMMR/MSI mCRC. The results showed that there was no improved outcome with CT after ICI failure, but prolonged disease control was observed in some cases.

CANCERS (2022)

Add to Collection

Article Medicine, General & Internal

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer A Randomized Clinical Trial

Niharika B. Mettu et al.

Summary: Cotargeting vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 may produce anticancer activity in refractory metastatic colorectal cancer (mCRC). This study aimed to evaluate the improvement of progression-free survival (PFS) by adding atezolizumab in patients with refractory mCRC and to explore the efficacy in patients with microsatellite-stable (MSS) disease and liver metastasis. The results showed limited clinical benefit of adding atezolizumab to capecitabine and bevacizumab therapy. Patients with MSS and proficient mismatch repair tumors and those without liver metastasis benefited more from the dual inhibition of the vascular endothelial growth factor and programmed cell death 1 or programmed cell death ligand 1 pathways.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Oncology

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano et al.

Summary: This trial evaluated the efficacy and safety of an immune-sensitizing strategy in patients with MSS and MGMT-silenced mCRC. The results showed that a combination of temozolomide priming followed by low-dose ipilimumab and nivolumab may induce durable clinical benefit in these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti et al.

Summary: The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improves progression-free survival in previously untreated metastatic colorectal cancer patients.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Dual HER2 Targeted Therapy With Pyrotinib and Trastuzumab in Refractory HER2 Positive Metastatic Colorectal Cancer: A Result From HER2-FUSCC-G Study

Jinjia Chang et al.

Summary: This study demonstrates that the combination of trastuzumab and pyrotinib has encouraging antitumor activity in HER2 positive refractory or metastatic colorectal cancer patients, with prolonged survival observed in RAS wild-type patients.

CLINICAL COLORECTAL CANCER (2022)

Add to Collection

Article Oncology

Translational analysis and final efficacy of the AVETUX trial - Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer

Joseph Tintelnot et al.

Summary: The AVETUX trial combined PD-L1 antibody avelumab with FOLFOX chemotherapy and cetuximab, finding that T cell clonality and diversity may serve as potential markers to predict response to chemo-immunotherapy combinations in MSS mCRC.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort

Y. Kuboki et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Oncology

Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Benny Johnson et al.

Summary: This study investigates the combination of trametinib with durvalumab in patients with refractory microsatellite stable metastatic colorectal cancer. The combination therapy demonstrated acceptable tolerability but did not meet the efficacy criteria to proceed to the second stage of the study. The specific site of metastatic disease may affect the outcomes in immunotherapy combination trials.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancer

J. Tabernero et al.

Summary: The addition of atezolizumab to FP/bevacizumab as first-line maintenance treatment after FOLFOX thorn bevacizumab induction did not improve efficacy outcomes for patients with BRAF wild-type metastatic colorectal cancer (mCRC).

ESMO OPEN (2022)

Add to Collection

Article Oncology

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study

Ranju Gupta et al.

Summary: This article presents the results of treating patients with colorectal cancer with either ERBB2 amplifications or ERBB2/3 mutations using pertuzumab plus trastuzumab. The combination treatment showed favorable outcomes for patients with ERBB2 amplifications, while it had limited effectiveness for patients with ERBB2/3 mutations. Further study is warranted for this treatment combination.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Oncology

Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status

Avraham Travers et al.

Summary: Optimal management of metastatic colorectal cancer patients with poor/very poor performance status remains a challenge, but real-world practice shows that many patients benefit clinically from treatment despite their poor performance status.

CLINICAL COLORECTAL CANCER (2021)

Add to Collection

Article Oncology

Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial

Sophie Cousin et al.

Summary: This study demonstrated that the combination of Regorafenib + avelumab has a synergistic effect in a subset of colorectal cancer patients, mobilizing antitumor immunity. Additionally, computational pathology through quantification of immune cell infiltration may improve patient selection for further studies investigating this approach.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Review Oncology

The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer

Mehran Pashirzad et al.

Summary: The MAPK/ERK signaling pathway plays a crucial role in the pathogenesis of colorectal cancer, with inhibitors such as MEK162 and MK-2206 showing promising efficacy in preclinical and clinical settings. MEK1/2 inhibitors demonstrate good therapeutic effects and anti-cancer activity for the treatment of CRC.

CURRENT CANCER DRUG TARGETS (2021)

Add to Collection

Meeting Abstract Oncology

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Joshua K. Sabari et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero et al.

Summary: The study evaluated different treatment regimens for patients with BRAF V600E-mutant metastatic colorectal cancer, showing that encorafenib plus cetuximab improved overall survival, objective response rate, and progression-free survival compared to standard chemotherapy.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer

Manish R. Patel et al.

Summary: In this study, MSS metastatic CRC patients were treated with FTD/TPI plus nivolumab, but no tumor response was achieved, and the study did not progress to the second stage. The most frequent adverse events during treatment were nausea, diarrhea, and neutropenia.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena et al.

Summary: This study aimed to investigate the antitumour activity and safety of trastuzurnab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. The drug showed promising and durable activity in HER2-positive metastatic colorectal cancer refractory to standard treatment, with a safety profile consistent with previous trials. However, careful monitoring and prompt intervention are required for important risks like interstitial lung disease and pneumonitis.

LANCET ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial

J-D. Fumet et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

The current understanding on the impact of KRAS on colorectal cancer

Mingjing Meng et al.

Summary: KRAS mutations are a major driver in CRC and significantly impact the prognosis and survival of patients. Research studies focus on exploring potential therapeutics for KRAS mutant CRC, as well as understanding the pathological consequences and treatment response of these mutations. Challenges and difficulties in treating KRAS mutant CRC are also discussed.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Article Oncology

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

Ho Wai Derrick Siu et al.

Summary: The MONARCC study aims to investigate the activity and tolerability of first-line panitumumab-based treatments in elderly patients with metastatic colorectal cancer. The study seeks to expand treatment options, maximize progression-free and overall survival, and improve quality of life in this population. It will explore the efficacy of chemotherapy approaches in metastatic colorectal cancer.

BMC CANCER (2021)

Add to Collection

Review Oncology

Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies

Lisa Salvatore et al.

Summary: The impact of single agent bevacizumab maintenance on metastatic colorectal cancer remains uncertain. While several studies have shown some benefits in terms of progression-free survival, the absolute improvement seems limited, especially for RAS wild-type patients. Maintenance therapy with fluoropyrimidine with or without bevacizumab remains the preferred option, with single agent bevacizumab maintenance considered for selected cases.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Son of Sevenless 1: The pacemaker of KRAS

Dirk Kessler et al.

Summary: Son of Sevenless (SOS) is a guanine nucleotide exchange factor that plays a key role in activating the important cell signaling switch KRAS. Inhibition of SOS1 with potent inhibitors like BI-3406 has shown promising antiproliferative effects against various oncogenic KRAS mutants. The first SOS1 inhibitor has entered clinical trials for KRAS-mutated cancers, highlighting the potential therapeutic significance of targeting this pathway.

CURRENT OPINION IN CHEMICAL BIOLOGY (2021)

Add to Collection

Article Oncology

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial

Erika Martinelli et al.

Summary: The study suggests that cetuximab plus avelumab is an effective and well-tolerated rechallenge therapy for RAS wild-type metastatic colorectal cancer. Plasma ctDNA analysis may help in selecting patients who could benefit from this treatment.

JAMA ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial

Benjamin Besse et al.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection

Article Oncology

Updated results from a phase Ib trial of regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer (REGONIVO, EPOC1603).

Kohei Shitara et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Caio Max Sao Pedro Rocha Lima et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

New genetic variations discovered in KRAS wild-type cetuximab resistant chinese colorectal cancer patients

Changwen Jing et al.

MOLECULAR CARCINOGENESIS (2020)

Add to Collection

Review Cell Biology

The future of cancer immunotherapy: microenvironment-targeting combinations

Yonina R. Murciano-Goroff et al.

CELL RESEARCH (2020)

Add to Collection

Article Oncology

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Marta Schirripa et al.

CLINICAL COLORECTAL CANCER (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi et al.

NATURE MEDICINE (2020)

Add to Collection

Article Oncology

Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer

Patricia Martin-Romano et al.

EUROPEAN JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial

Andrea Sartore-Bianchi et al.

ESMO OPEN (2020)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

T. Andre et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Medicine, General & Internal

Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer

Albert Tuca et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Meeting Abstract Oncology

PEMBROLIZUMAB IN COMBINATION WITH XELOX BEVACIZUMAB IN PATIENTS WITH MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND A HIGH IMMUNE INFILTRATE: A PROOF OF CONCEPT STUDY. FFCD 1703 POCHI

David Tougeron et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Oncology

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

M. D. Hellmann et al.

ANNALS OF ONCOLOGY (2019)

Add to Collection

Article Oncology

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

Funda Meric-Bemstam et al.

LANCET ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.

Salvatore Siena et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

Filippo Pietrantonio et al.

JAMA ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials

Omar Abdel-Rahman

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2019)

Add to Collection

Meeting Abstract Oncology

Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

David Hyman et al.

CANCER RESEARCH (2019)

Add to Collection

Article Oncology

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Francesca Battaglin et al.

BMC CANCER (2018)

Add to Collection

Review Oncology

The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review

Nele Boeckx et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)

Add to Collection

Article Oncology

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Michael J. Overman et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

E. Aranda et al.

EUROPEAN JOURNAL OF CANCER (2018)

Add to Collection

Meeting Abstract Oncology

Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.

Johanna C. Bendell et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Oncology

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Sandrine Aspeslagh et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Review Oncology

Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes

Sebastian Stintzing et al.

EUROPEAN JOURNAL OF CANCER (2017)

Add to Collection

Article Oncology

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

Alexander Drilon et al.

CANCER DISCOVERY (2017)

Add to Collection

Article Oncology

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers

Mohamed E. Salem et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study

K. K. H. Goey et al.

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

S. Y. Brule et al.

EUROPEAN JOURNAL OF CANCER (2015)

Add to Collection

Article Oncology

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini et al.

LANCET ONCOLOGY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

The consensus molecular subtypes of colorectal cancer

Justin Guinney et al.

NATURE MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Oncology

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

Sabine Venderbosch et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

J. C. von Einem et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)

Add to Collection

Article Oncology

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

Chengwen Liu et al.

CLINICAL CANCER RESEARCH (2013)

Add to Collection

Article Oncology

Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study

Luca Moscetti et al.

INVESTIGATIONAL NEW DRUGS (2013)

Add to Collection

Article Oncology

Bevacizumab plus Capecitabine as Maintenance Therapy after Initial Bevacizumab plus XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase Ill 'Stop and Go' Study Results - A Turkish Oncology Group Trial

Suayib Yalcin et al.

ONCOLOGY (2013)

Add to Collection

Article Oncology

Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients

Cirino Botta et al.

JOURNAL OF IMMUNOTHERAPY (2012)

Add to Collection

Article Oncology

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

C. Bokemeyer et al.

ANNALS OF ONCOLOGY (2011)

Add to Collection

Article Oncology

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAFV600E mutation

Jeanne Tie et al.

INTERNATIONAL JOURNAL OF CANCER (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.